Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Meridian illumigene C difficile assay secures Canadian license

Meridian Bioscience, a manufacturer of immunoassay C difficile tests, has received an approved medical device license from Health Canada for its new molecular amplification assay, illumigene C difficile.

The illumigene molecular amplification assay detects the presence of the toxin producing region from the C difficile DNA, and provides accurate results in under an hour.

Meridian claims that the new illumigene C difficile molecular diagnostic system provides high levels of sensitivity for diagnosing the infectious disease and its simple workflow requires minimal hands-on time per sample and the product has been recently launched successfully in the US as well as in Australia, Taiwan and most European markets.

Meridian chief executive officer Jack Kraeutler said that toxin producing C difficile infections, especially in hospitalised patients, can have especially devastating consequences if not diagnosed and treated quickly.

“Because disease symptoms of C difficile infection can strike patients at any hour of the day or night, Meridian designed illumigene C difficile to enable real-time molecular testing in any lab at any time and with minimal hands-on time and virtually no capital expense, illumigene gives any infectious disease lab access to a convenient and powerful DNA amplification platform,” Kraeutler said.